Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CG Oncology (CGON) FCF Margin (2023 - 2025)

CG Oncology's FCF Margin history spans 3 years, with the latest figure at 1558.01% for Q4 2025.

  • For Q4 2025, FCF Margin rose 301896.0% year-over-year to 1558.01%; the TTM value through Dec 2025 reached 3278.07%, up 365319.0%, while the annual FY2025 figure was 3278.07%, 365319.0% up from the prior year.
  • FCF Margin reached 1558.01% in Q4 2025 per CGON's latest filing, up from 2342.56% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 1558.01% in Q4 2025 to a low of 1464500.0% in Q4 2023.
  • Average FCF Margin over 3 years is 172614.44%, with a median of 9727.3% recorded in 2024.
  • Peak YoY movement for FCF Margin: soared 145992303bps in 2024, then tumbled -5141322bps in 2025.
  • A 3-year view of FCF Margin shows it stood at 1464500.0% in 2023, then soared by 100bps to 4576.97% in 2024, then surged by 66bps to 1558.01% in 2025.
  • Per Business Quant, the three most recent readings for CGON's FCF Margin are 1558.01% (Q4 2025), 2342.56% (Q3 2025), and 56332.69% (Q1 2025).